[1] A second large randomized trial of similar design (404 patients, with a 6-month efficacy phase and a 6-month extension) reproduced the effect, and patients who continued tesamorelin to 12 months showed a sustained VAT reduction of roughly 18%
Resources: Pickart, L., & Margolina, A
Advances in Neural Computation, Machine Learning, and Cognitive Research III
SKU: CP10 Category: Blended Tags: Beginner, CJC-1295 (No DAC) + Ipamorelin research, Fat Loss, GH research, GH Stimulation / Fat Loss, GHRH Analogues, growth hormone peptide, Recomp Frequently Bought Together In Stock In Stock In Stock In Stock In Stock In Stock In Stock In Stock In Stock Related Products In Stock In Stock In Stock In Stock In Stock In Stock In Stock In Stock In Stock In Stock